[Federal Register Volume 72, Number 28 (Monday, February 12, 2007)]
[Notices]
[Pages 6579-6580]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-2320]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on December 12, 2006, Orasure 
Technologies, Inc., Lehigh University, Seeley G Mudd-Building 6, 220 
East First Street, Bethlehem, Pennsylvania 18015, made application by 
renewal to the Drug Enforcement Administration (DEA) as a bulk 
manufacturer of the basic classes of controlled substances listed in 
schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Lysergic acid diethylamide (LSD) (7315)....  I
4-Methoxyamphetamine (7411)................  I
Normorphine (9313).........................  I
Tetrahydrocannabinols (THC) (7370).........  I
Alphamethadol (9605).......................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Cocaine (9041).............................  II
Hydromorphone (9150).......................  II
Benzoylecgonine (9180).....................  II
Hydrocodone (9193).........................  II
Morphine (9300)............................  II
Oxycodone (9143)...........................  II
Meperidine (9230)..........................  II
Methadone (9250)...........................  II
Oxymorphone (9652).........................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk to manufacture controlled substance derivatives. These 
derivatives will be used in diagnostic products created specifically 
for internal use only.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Deputy Assistant 
Administrator,

[[Page 6580]]

Office of Diversion Control, Drug Enforcement Administration, 
Washington, DC 20537, Attention: DEA Federal Register Representative/
ODL; or any being sent via express mail should be sent to DEA 
Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 
Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed 
no later than April 13, 2007.

     Dated: February 5, 2007.
 Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E7-2320 Filed 2-9-07; 8:45 am]
BILLING CODE 4410-09-P